1. Search Result
Search Result
Results for "

MSSA

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

4

Peptides

4

Natural
Products

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100180
    Delpazolid
    1 Publications Verification

    LCB01-0371

    Bacterial Antibiotic Infection
    Delpazolid is a novel oxazolidinone antibiotic agent which can inhibit the growth of MSSA and MRSA with a MIC90 of 2 μg/mL for both of them.
    Delpazolid
  • HY-B2234
    Povidone iodine
    2 Publications Verification

    iodopovidone

    Environmental Pollutants Bacterial Infection
    Povidone iodine (iodopovidone) displays excellent antibacterial activity which can against MRSA and MSSA strains with MICs of 31.25 mg/L and 7.82 mg/L, respectively.
    Povidone iodine
  • HY-133119

    Bacterial Infection
    PK150, an analogue of Sorafenib, shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 μM, respectively .
    PK150
  • HY-18702

    Bacterial Infection
    Targocil functions as a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis which can inhibit the growth of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) with MIC90s of 2 μg/ mL for both MRSA and MSSA.
    Targocil
  • HY-14926

    (S)-(-)-Nadifloxacin; WCK 771

    Antibiotic Bacterial Infection
    Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
    Levonadifloxacin
  • HY-14956
    Nemonoxacin
    1 Publications Verification

    TG-873870

    Antibiotic Bacterial Infection Inflammation/Immunology
    Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .
    Nemonoxacin
  • HY-103645
    GW779439X
    1 Publications Verification

    Bacterial Aurora Kinase Apoptosis Infection Cancer
    GW779439X is a pyrazolopyridazine identified in an inhibitor of the S. aureus PASTA kinase Stk1. GW779439X potentiates the activity of β-lactam antibiotics against various MRSA and MSSA isolates, some even crossing the breakpoint from resistant to sensitive. GW779439X is an AURKA inhibitor and induces apoptosis by the caspases 3/7 pathway . MRSA:methicillin-resistant S. aureus; MSSA: methicillin-sensitive S. aureus
    GW779439X
  • HY-146330

    Bacterial Infection
    FtsZ-IN-2 (Compound 19) is an inhibitor of the bacterial cell division protein FtsZ with GTPase inhibitory activity. FtsZ-IN-2 exhibits anti-staphylococcal activity with MIC values of 2 µg/ml for MSSA and MRSA .
    FtsZ-IN-2
  • HY-147960

    Glycosyltransferase Infection
    Glycosyltransferase-IN-1 (compound 5m) is a potent glycosyltransferase inhibitor, with an IC50 of 82.8 μM. Glycosyltransferase-IN-1 shows antibacterial activity, with MIC values of 6 μg/mL for MSSA, MRSA, B. subtilis and 12 μg/mL for E. coli .
    Glycosyltransferase-IN-1
  • HY-164051
    1650-M15
    1 Publications Verification

    Bacterial Infection
    1650-M15 is an inhibitor of lipoteichoic acid synthase (LtaS). It has inhibitory activity against Gram-positive bacteria but has no significant inhibitory effect against Gram-negative bacteria. The IC50s of 1650-M15 against MRSA and MSSA are 62.44 μM and 66.42 μM, respectively, and the MICs are both 200 μM .
    1650-M15
  • HY-P5206

    Bacterial Infection
    Garvicin KS, GakB is a peptide at sizes of 34 amino acids to form bacteriocin garvicin KS (GarKS), with other 2 peptides, GakA, and GakC. Garvicin KS, GakB inhibits fibroblast viability and proliferation. Garvicin KS, GakB with GakA, is a potent combination with good peptide stability, antimicrobial efficacy, and fibroblast viability/proliferation effects. Garvicin KS peptides inhibit MSSA with MIC values in the order GakB >GakC >GakA .
    Garvicin KS, GakB
  • HY-P5205

    Bacterial Infection
    Garvicin KS, GakA is a peptide at sizes of 34 amino acids to form bacteriocin garvicin KS (GarKS), with other 2 peptides, GakB, and GakC. Garvicin KS, GakA inhibits fibroblast viability and proliferation. Garvicin KS, GakA with GakB, is a potent combination with good peptide stability, antimicrobial efficacy, and fibroblast viability/proliferation effects. Garvicin KS peptides inhibit MSSA with MIC values in the order GakB >GakC >GakA .
    Garvicin KS, GakA
  • HY-142097

    Bacterial Infection
    Glicophenone is an antibacterial agent with MICs of both 32 μg/mL against MRSA OM481, MRSA OM505, MRSA OM584, MRSA OM623 and MSSA 209P .
    Glicophenone
  • HY-168486

    Bacterial Infection
    Biotin protein ligase-IN-1 (Compound Bio-9) is an inhibitor of biotin protein ligase (BPL) with a Kd value of 7 nM. Biotin protein ligase-IN-1 exhibits antibacterial activity, with MIC values of 0.2 and 20 μM against Staphylococcus aureus (including MRSA and MSSA) and Mycobacterium tuberculosis, respectively .
    Biotin protein ligase-IN-1
  • HY-108021

    Bacterial Infection
    HT-61 is a quinolone antibacterial agent. HT-61 exhibits bactericidal activity against gram-positive bacteria including methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). HT-61 can enhance the effect of Tobramycin (HY-B0441) against Pseudomonas aeruginosa .
    HT-61
  • HY-175723

    Bacterial Monoamine Oxidase Infection
    MAO-A/B-IN-4 is an orally active MAO-A/B inhibitor, with IC50 values of 51.3 μM and 47.0 μM, respectively. MAO-A/B-IN-4 exhibits potent activity against S. aureus, MSSA, MRSA, LRSA, and LREFa. MAO-A/B-IN-4 demonstrates potent antibacterial efficacy in a mouse model of LRSA peritonitis infection. MAO-A/B-IN-4 can be used for the study of bacterial infections .
    MAO-A/B-IN-4
  • HY-125424

    Bacterial Inflammation/Immunology
    AM8191 is an orally active bactericidal and selectively inhibits DNA synthesis and Staphylococcus aureus gyrase (IC50=1.02 μM) and topo IV (IC50=10.4 μM). AM8191 inhibits S. aureus MSSA (MIC=0.02 μg/mL) and S. aureus MRSA (MIC=0.06 μg/mL) .
    AM8191 hydrochloride
  • HY-122008

    Bacterial Infection
    Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) arginine is a broad-spectrum antistaphylococcal agent. Levonadifloxacin arginine has antimicrobial activity against methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus and reduces phagocytosis of MRSA and MSSA strains by monocytic THP-1.
    ORM-3819
  • HY-14926B

    (S)-(-)-Nadifloxacin arginine; WCK 771 arginine

    Bacterial Infection
    Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) arginine is a broad-spectrum antistaphylococcal agent. Levonadifloxacin arginine has antimicrobial activity against methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus and reduces phagocytosis of MRSA and MSSA strains by monocytic THP-1 cells .
    Levonadifloxacin arginine
  • HY-150983

    ATP Synthase Bacterial Infection
    ATP synthase inhibitor 2 is a Pseudomonas aeruginosa (PA) ATP synthase inhibitor (IC50=10 μg/mL). ATP synthase inhibitor 2 can inhibit Pseudomonas aeruginosa (PA) ATP synthesis activity completely at 128 μg/mL .
    ATP synthase inhibitor 2
  • HY-150983A

    ATP Synthase Bacterial Infection
    ATP synthase inhibitor 2 (Compound 22) TFA is a Pseudomonas aeruginosa (PA) ATP synthase inhibitor (IC50=10 μg/mL). ATP synthase inhibitor 2 TFA can inhibit Pseudomonas aeruginosa (PA) ATP synthesis activity completely at 128 μg/mL .
    ATP synthase inhibitor 2 TFA
  • HY-163762

    Bacterial Infection
    Antibacterial agent 226 (Compound 7f) is an antibacterial agent, that inhibits Staphylococcus aureus strains and methicillin-resistant S. aureus strain with MIC of 2 μg/mL. Antibacterial agent 226 exhibits cytotoxicity to HEK293 with IC50 of 1.9 μM .
    Antibacterial agent 226
  • HY-151937

    Bacterial Infection
    Antibacterial agent 127 (Compound 23) is a potent antibacterial agent .
    Antibacterial agent 127
  • HY-14926A

    (S)-(-)-Nadifloxacin arginine hydrate; WCK-771A arginine hydrate

    Antibiotic Bacterial Infection
    Levonadifloxacin (arginine) hydrate is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin (arginine) hydrate shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
    Levonadifloxacin arginine hydrate
  • HY-P5207

    Bacterial Infection
    Garvicin KS, GakC is a peptide at sizes of 32 amino acids to form bacteriocin garvicin KS (GarKS), with other 2 peptides, GakA, and GakB. Garvicin KS, GakC inhibits fibroblast viability and proliferation. Garvicin KS peptides inhibit MSSA with MIC values in the order GakB >GakC >GakA .
    Garvicin KS, GakC
  • HY-14926R

    (S)-(-)-Nadifloxacin (Standard); WCK 771 (Standard)

    Reference Standards Antibiotic Bacterial Infection
    Levonadifloxacin (Standard) is the analytical standard of Levonadifloxacin. This product is intended for research and analytical applications. Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
    Levonadifloxacin (Standard)
  • HY-125533

    Bacterial Infection
    TXA497 is a potent local topical bactericide. TXA497 exerts its bactericidal effect by interfering with the polymerization kinetics of the bacterial cell division protein FtsZ, rather than inhibiting it. TXA497 shows strong activity against various Staphylococcus aureus strains, including MRSA and MSSA, with an MIC value ranging from 1.0 to 2.0 μg/mL. TXA497 skin deposition is concentration-dependent in its formulation, consistent with Fick's first law. TXA497 has limited systemic permeability through the lipid pathway of the stratum corneum and is easily absorbed through this route. TXA497 can be used for research on topical bactericidal agents .
    TXA497
  • HY-151458

    VEGFR Bacterial Dihydrofolate reductase (DHFR) Fungal Infection Cancer
    VEGFR-2/DHFR-IN-1 (compound 8b) is an inhibitor of VEGFR-2 and DHFR with IC50s of 0.384 and 7.881 μM, respectively. VEGFR-2/DHFR-IN-1 shows good antibacterial activities against Escherichia coli, Streptococcus faecalis, Salmonella enterica, MSSA and MRSA with MIC values of 16, 16, 16, 8, and 16 μg/mL, respectively. VEGFR-2/DHFR-IN-1 exhibits good cytotoxic activities against C26, HepG2, and MCF7 cancer cell lines with IC50 values of 2.97-7.12 μM. VEGFR-2/DHFR-IN-1 can be used for the research of cancer .
    VEGFR-2/DHFR-IN-1
  • HY-N16526

    Bacterial Infection
    Juncatrin B is a type of dihydrophenanthrene compound. Juncatrin B exhibits inhibitory activity against both Methicillin (HY-121544)-sensitive Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA). Juncatrin B can inhibit the formation of biofilms in MSSA and MRSA. Juncatrin B has no significant activity against Gram-negative bacteria. Juncatrin B can be used in the research of anti-Staphylococcus aureus .
    Juncatrin B
  • HY-103645R

    Reference Standards Bacterial Aurora Kinase Apoptosis Infection Cancer
    GW779439X (Standard) is the analytical standard of GW779439X (HY-103645). This product is intended for research and analytical applications. GW779439X is a pyrazolopyridazine identified in an inhibitor of the S. aureus PASTA kinase Stk1. GW779439X potentiates the activity of β-lactam antibiotics against various MRSA and MSSA isolates, some even crossing the breakpoint from resistant to sensitive. GW779439X is an AURKA inhibitor and induces apoptosis by the caspases 3/7 pathway . MRSA:methicillin-resistant S. aureus; MSSA: methicillin-sensitive S. aureus
    GW779439X (Standard)
  • HY-N16702

    Drug Derivative Others
    8-Demethyleucalyptin is a natural flavonoid.
    8-Demethyleucalyptin
  • HY-P11622

    Drug Derivative Infection
    Gramicidin S analogue 9 is a bactericidal agent that can be found as a cyclic peptide analogue. Gramicidin S analogue 9 disrupts bacterial cell membranes. Gramicidin S analogue 9 can be used for the research of methicillin-resistant staphylococcus aureus infection .
    Gramicidin S analogue 9
  • HY-185443

    Bacterial Dihydrofolate reductase (DHFR) Infection
    UCP1172 is an antibacterial (Antibacterial) agent and Dihydrofolate reductase inhibitor, with an IC50 of 0.0089 μM against Staphylococcus aureus DfrB, 0.22 μM against DfrG, 0.41 μM against DfrA, and 0.030 μM against DfrK. UCP1172 potently inhibits the growth of MRSA/MSSA isolates carrying dfrG and dfrK (MIC values of 0.3125-0.625 μg/mL), shows weak activity against MRSA carrying dfrA (MIC of 5 μg/mL), and exerts extremely potent inhibitory effects on wild-type S. aureus ATCC 43300 (MIC of 0.0098 μg/mL). UCP1172 can be used in studies related to tuberculosis and Staphylococcus aureus infections .
    UCP1172
  • HY-182461

    Bacterial Infection
    Deoxymorellin is a caged xanthone found in resins and fruits of Garcinia hanburyi hook. f.. Deoxymorellin exhibits cytotoxicity. Deoxymorellin can be used for research of Methicillin (HY-121544)-resistant or Methicillin-susceptible Staphylococcus aureus .
    Deoxymorellin
  • HY-182022

    Bacterial Reactive Oxygen Species (ROS) Drug Derivative DNA/RNA Synthesis Infection
    ZLWH-67 is a β-Carboline derivative and Antibacterial agent. ZLWH-67 inhibits DNA synthesis, suppresses biofilm formation, and increases reactive oxygen species (ROS) levels. ZLWH-67 exhibits potent in vitro antibacterial activity against MRSA (MIC = 0.5-4 μg/mL), S. epidermidis (MIC = 4 μg/mL), E. faecalis (MIC = 4-8 μg/mL), and S. pneumoniae (MIC = 16 μg/mL). ZLWH-67 displays anti-MRSA effects in murine skin and pneumonia infection models .
    ZLWH-67

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: